Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.
NSCLC Stage II|NSCLC, Stage IIIA|NSCLC, Stage I
DRUG: Nivolumab 10 MG/ML Intravenous Solution|DRUG: Relatlimab 10 MG/ML Intravenous Solution
Feasibility of four weeks of preoperative immunotherapy with Nivolumab, Nivolumab plus Relatlimab (80 mg), and Nivolumab plus Relatlimab (240 mg), Within 43 days after first study medication
Estimation of pathological tumor response rate, Within 43 days after first study medication (day of surgery)|Estimation of curative (R0) resection rate, Within 43 days after first study medication (day of surgery)|Objective radiological response rate, Objective radiological response rate per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, After 3, 6, 9 and 12 months post-surgery|Disease-free survival rate at 12 months, Assessment of disease-free survival rate at 12 months per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, 12 months|Overall survival rate at 12 months, 12 months|Morbidity, Estimation of morbidity within 90 days after surgery, within 90 days after surgery|Mortality, Estimation of mortality within 90 days after surgery, within 90 days after surgery
The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.